(8 years, 7 months ago)
Commons Chamber15. What the timetable is for the launch of the public consultation on HIV pre-exposure prophylaxis for adults at high risk of contracting HIV.
NHS England will invest £2 million over the next two years in order to run, together with Public Health England, early implementer test sites which will seek to answer the remaining questions about how PrEP could be commissioned in the most cost-effective and integrated way to reduce the incidence of HIV and sexually transmitted infections for those at the highest risk.
Yesterday NHS England scrapped plans to fund PrEP. Is there anything that the Minister can do to end this erratic and inconsistent decision making? Does she agree that yesterday’s decision to abandon the roll-out of a game-changing drug totally failed those who are at risk of contracting HIV?
NHS England’s senior specialised commissioning management team made that decision, and I think NHS England recognises that it could have been made earlier. However, it is also recognised that NHS England has already done valuable work. Some important lessons have been learned, and we do not want to lose that. We must now work with both NHS England and Public Health England to understand how we can continue to learn from, for example, the test sites.
(8 years, 10 months ago)
Commons ChamberUrgent Questions are proposed each morning by backbench MPs, and up to two may be selected each day by the Speaker. Chosen Urgent Questions are announced 30 minutes before Parliament sits each day.
Each Urgent Question requires a Government Minister to give a response on the debate topic.
This information is provided by Parallel Parliament and does not comprise part of the offical record
I would never give a yes or no answer to the individual health problems of a constituent I do not know, and I am not a clinician, but if my hon. Friend would like to write to me, I will certainly make sure I give an individualised response. Ultimately, however, the right clinical route for any one individual would come at the suggestion of their consultant hepatologist. Towards the end of November, NICE published new guidelines on three more drug treatments, so the drug landscape for hepatitis C is changing rapidly, but I am happy to ensure that hon. Members are kept fully informed. As I said in a previous debate, if people are concerned that their constituents are not aware of what is out there or do not feel they are getting the support they need to access treatment in line with the NICE guidance, we can offer advice to Members on how to make sure that happens. However, I am well aware of the general point he makes.
Will the Minister clarify whether individuals affected by this terrible scandal will receive individualised letters? How will they know that this consultation is opening next month?
My officials have been giving considerable thought to how to do that. A number of people are members of the existing schemes, so we have a means to communicate with them, but it is clear from experience of following up previous inquiries’ recommendations—for example, the one recommendation of the Penrose inquiry—that we make exhaustive efforts to inform everybody. In particular, we will want to inform people who have had a lump sum payment but are not members of the current scheme. We will make exhaustive efforts to inform people by every means possible. Members of Parliament can of course be of great assistance in that regard.